We aimed to evaluate the outcome of transurethral resection of the prostate (TURP) in patients with benign prostatic hyperplasia (BPH) and diagnosed to have weak detrusor contractility by urodynamic study.
To date, the existing literature on the natural history, growth, and progression patterns of small renal masses (SRMs) has not been informed by a histology-specific approach. In addition, we know that up to 30% of SRMs are not renal cell carcinoma (RCC), thus study cohorts have been heterogeneous and do not reflect RCC subtype malignant […]
Background Underinsured patients face significant barriers in accessing high‐quality care. Evidence of whether access to high‐volume surgical care is mediated by disparities in health insurance coverage remains wanting. Methods The authors used the National Cancer Data Base to identify all adult patients who had a confirmed diagnosis of breast, prostate, lung, or colorectal cancer during […]
Atlanta, Georgia (UroToday.com) Dr. Samir Taneja from New York, New York, presented on the “Integration of MRI in the Prostate Cancer Diagnostic Pathway” at the 2020 Prostate Cancer Academy.
The accurate selection of patients who are most likely to benefit from neoadjuvant chemotherapy is an important challenge in oncology. Serum AGR has been found to be associated with oncological outcomes in various malignancies.
N6-Methyladenosine (m6A) refers to the methylation modification occurring at the nitrogen-6 position of adenosine. Many human physiological processes such as modulation of spermatogenesis are caused by m6A RNA modifications.
A high density of CD8+ tumor infiltrating lymphocytes (TILs) is associated with improved survival in multiple cancers, but its prognostic role in prostate cancer remains controversial. The aim of our study was to evaluate the prognostic value of CD8+ TILs in prostate cancer patients undergoing radical prostatectomy (RP).
To compare standard (RARP) and Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) in a multi-centre study using prospective patient-reported outcome measures (PROMs) of functional recovery and quality-of-life (QOL), plus standard pentafecta outcomes.
Androgen deprivation therapy (ADT) remains the standard therapy for patients with oligometastatic prostate cancer (OMPC). Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT)-based stereotactic body radiotherapy (SBRT) is emerging as an alternative option to postpone starting ADT and its associated side effects including the development of drug resistance.
Prostate cancer is now the second-most common cancer in many parts of India. Despite being the second-largest population in the world, data regarding outcomes of biopsy in Indian men are limited. We report the correlation of biopsy finding with prostate-specific antigen (PSA) level in Indian men undergoing biopsy for either elevated PSA and/or abnormal digital […]
